结合表观遗传学和免疫疗法对抗癌症。
Combining Epigenetic and Immunotherapy to Combat Cancer.
作者信息
Chiappinelli Katherine B, Zahnow Cynthia A, Ahuja Nita, Baylin Stephen B
机构信息
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
出版信息
Cancer Res. 2016 Apr 1;76(7):1683-9. doi: 10.1158/0008-5472.CAN-15-2125. Epub 2016 Mar 17.
Abstract
The most exciting recent advance for achieving durable management of advanced human cancers is immunotherapy, especially the concept of immune checkpoint blockade. However, with the exception of melanoma, most patients do not respond to immunotherapy alone. A growing body of work has shown that epigenetic drugs, specifically DNA methyltransferase inhibitors, can upregulate immune signaling in epithelial cancer cells through demethylation of endogenous retroviruses and cancer testis antigens. These demethylating agents may induce T-cell attraction and enhance immune checkpoint inhibitor efficacy in mouse models. Current clinical trials are testing this combination therapy as a potent new cancer management strategy. Cancer Res; 76(7); 1683-9. ©2016 AACR.
摘要
实现晚期人类癌症持久治疗的最令人兴奋的最新进展是免疫疗法，尤其是免疫检查点阻断的概念。然而，除黑色素瘤外，大多数患者对单独的免疫疗法没有反应。越来越多的研究表明，表观遗传药物，特别是DNA甲基转移酶抑制剂，可以通过对内源性逆转录病毒和癌胚抗原进行去甲基化来上调上皮癌细胞中的免疫信号。这些去甲基化剂可能会在小鼠模型中诱导T细胞吸引并增强免疫检查点抑制剂的疗效。目前的临床试验正在测试这种联合疗法作为一种有效的新癌症治疗策略。《癌症研究》；76(7)；1683 - 9。©2016美国癌症研究协会。
相似文献
1
Combining Epigenetic and Immunotherapy to Combat Cancer.结合表观遗传学和免疫疗法对抗癌症。
Cancer Res. 2016 Apr 1;76(7):1683-9. doi: 10.1158/0008-5472.CAN-15-2125. Epub 2016 Mar 17.
2
A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.癌症治疗新趋势：表观遗传学与免疫疗法的联合。
Front Immunol. 2022 Jan 24;13:809761. doi: 10.3389/fimmu.2022.809761. eCollection 2022.
3
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?从患者权益倡导者的角度来看：癌症免疫疗法是否代表了一种范式转变？
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
4
[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?].免疫疗法与化疗或其他免疫检查点抑制剂联合使用的地位如何？
Bull Cancer. 2017 May;104(5):485-493. doi: 10.1016/j.bulcan.2017.03.008. Epub 2017 Apr 19.
5
Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.乳腺癌的联合放射治疗与免疫检查点阻断治疗
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. doi: 10.1016/j.ijrobp.2017.05.029. Epub 2017 May 26.
6
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.免疫疗法中的表观遗传修饰剂：聚焦于检查点抑制剂。
Immunotherapy. 2016 Jun;8(6):705-19. doi: 10.2217/imt-2016-0014.
7
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?联合免疫治疗和抗癌药物：实现癌症治愈的正确途径？
Ann Oncol. 2015 Sep;26(9):1813-1823. doi: 10.1093/annonc/mdv209. Epub 2015 Apr 28.
8
Leveraging epigenetics to enhance the efficacy of immunotherapy.利用表观遗传学提高免疫疗法的疗效。
Clin Epigenetics. 2021 May 17;13(1):115. doi: 10.1186/s13148-021-01100-x.
9
Propelling Immunotherapy Combinations Into the Clinic.推动免疫疗法联合方案进入临床应用。
Oncology (Williston Park). 2015 Dec;29(12):990-1002.
10
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.组蛋白去乙酰化酶抑制剂与免疫疗法联合进行的表观遗传调控
Epigenomics. 2015;7(4):641-52. doi: 10.2217/epi.15.16.
引用本文的文献
1
The Role of Human Endogenous Retroviruses in the Initiation and Progression of Melanoma.人类内源性逆转录病毒在黑色素瘤发生和发展中的作用
Biomedicines. 2025 Jul 8;13(7):1662. doi: 10.3390/biomedicines13071662.
2
Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes.通过抑制染色质修饰酶实现癌细胞类型特异性转座元件去抑制
Commun Biol. 2025 Jul 3;8(1):992. doi: 10.1038/s42003-025-08413-0.
3
Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma.用于增强免疫检查点抑制剂治疗黑色素瘤疗效的表观遗传修饰剂。
Transl Oncol. 2025 Jun 23;59:102452. doi: 10.1016/j.tranon.2025.102452.
4
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer.增强癌症中靶向ERV疫苗疗效的联合治疗方法
Cancer Immunol Res. 2025 Jun 4;13(6):792-803. doi: 10.1158/2326-6066.CIR-24-1192.
5
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives.表观遗传调节剂与肿瘤免疫疗法：现状与展望
Clin Epigenetics. 2025 Mar 21;17(1):51. doi: 10.1186/s13148-025-01856-6.
6
Epigenetic drugs in cancer therapy.用于癌症治疗的表观遗传药物。
Cancer Metastasis Rev. 2025 Feb 26;44(1):37. doi: 10.1007/s10555-025-10253-7.
7
HERV Modulation in Colorectal Carcinoma Patients: A Snapshot of Endogenous Retroviral Transcriptome.结直肠癌患者中的人内源性逆转录病毒调节：内源性逆转录病毒转录组概览
J Med Virol. 2025 Mar;97(3):e70249. doi: 10.1002/jmv.70249.
8
DNMT3a promotes LUAD cell proliferation and metastasis by activating the HDAC7 signalling pathway.DNA甲基转移酶3a通过激活组蛋白去乙酰化酶7信号通路促进肺腺癌细胞的增殖和转移。
Int J Biol Sci. 2025 Jan 27;21(4):1585-1602. doi: 10.7150/ijbs.96509. eCollection 2025.
9
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma.用于预测转移性透明细胞肾细胞癌免疫治疗疗效的双人类内源性逆转录病毒分层系统。
J Immunother Cancer. 2025 Jan 22;13(1):e010386. doi: 10.1136/jitc-2024-010386.
10
5-Aza-2'-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells.5-氮杂-2'-脱氧胞苷（地西他滨）可增加头颈部鳞状细胞癌中癌胚抗原的表达，并改变免疫检查点的表达，尤其是在CD39阳性的CD8和CD4 T细胞中。
Neoplasia. 2025 Jan;59:101086. doi: 10.1016/j.neo.2024.101086. Epub 2024 Nov 27.
本文引用的文献
1
Epigenetic Determinants of Cancer.癌症的表观遗传决定因素
Cold Spring Harb Perspect Biol. 2016 Sep 1;8(9):a019505. doi: 10.1101/cshperspect.a019505.
2
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.抑制DNA甲基化会通过包括内源性逆转录病毒在内的双链RNA在癌症中引发干扰素反应。
Cell. 2015 Aug 27;162(5):974-86. doi: 10.1016/j.cell.2015.07.011.
3
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.DNA去甲基化剂通过诱导内源性转录本产生病毒模拟来靶向结肠直肠癌细胞。
Cell. 2015 Aug 27;162(5):961-73. doi: 10.1016/j.cell.2015.07.056.
4
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.地西他滨增强淋巴细胞迁移和功能，并与 CTLA-4 阻断在小鼠卵巢癌模型中协同作用。
Cancer Immunol Res. 2015 Sep;3(9):1030-41. doi: 10.1158/2326-6066.CIR-15-0073. Epub 2015 Jun 8.
5
Manipulation of B-cell responses with histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂对 B 细胞反应的调控。
Nat Commun. 2015 Apr 27;6:6838. doi: 10.1038/ncomms7838.
6
Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells.人类植入前胚胎和多能细胞中的内源性逆转录病毒激活
Nature. 2015 Jun 11;522(7555):221-5. doi: 10.1038/nature14308. Epub 2015 Apr 20.
7
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
8
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.癌症治疗中的免疫检查点靶向治疗：迈向具有治愈潜力的联合策略。
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
9
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
10
Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma.对T细胞进行基因工程改造以靶向人内源性逆转录病毒K（HERV-K），这是一种存在于黑色素瘤中的古老逆转录病毒。
Clin Cancer Res. 2015 Jul 15;21(14):3241-51. doi: 10.1158/1078-0432.CCR-14-3197. Epub 2015 Mar 31.
Zotero 插件